You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康哲药业(00867.HK)强烈否认杀人鲸资本指控 周一复牌
阿思达克 02-09 09:23

康哲药业(00867.HK)声明,强烈否认杀人鲸资本提出针对公司之各项指控,认为该等指控毫无根据且具严重误导性,并就指控反驳,其中主要包括:

公司自上市以来,财务报表均由国际四大会计师事务所审核,并出具无保留意见审计报告。公司於年度报告中披露关於利润的财务资料汇总了国际业务和国内业务利润,而杀人鲸资本於该报告中仅统计了集团国内业务涉及的两个主要子公司之利润,并未统计国际业务子公司利润,妄下判断该两间子公司代表了整个集团的业务;

马来西亚公司国际贸易是真实存在的,出於运营效率和成本节约考虑,进口产品实物未经过马来西亚,而由集团从海外生产厂家直接发货到香港或中国,这是国际转口贸易常态;

公司在香港上市前,将其研发业务分拆到康哲研究,康哲研究的股东除了主席外还有其他股东。分拆时CMS024项目的相关权利属公司,後续研究费用由康哲研究承担,公司并无秘密支付本应由A&B(即主席之私人公司)承担的研发费用;及CMS024成功商业化後公司向康哲研究支付13%专利费。

公司股份申请周一(10日)恢复买卖。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account